Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • News and press coverage
    • Stock information
    • Governance
    • Documentation

Corporate

15 October 2020

GenSight Biologics Reports Cash Position as of September 30, 2020 and Provides Operational Update

14 October 2020

GenSight Biologics Appoints Elsy Boglioli to its Board of Directors

12 Oct 2020 - 16 Oct 2020

Cell & Gene Meeting on the Mesa – Virtual

05 Oct 2020 - 06 Oct 2020

HealthTech Innovation Days (HTID®), Paris, France & Virtual Conference

05 Oct 2020 - 06 Oct 2020

Chardan 4th Annual Genetic Medicines Conference – Virtual

28 September 2020

GenSight Biologics Announces Publication of Meta-Analysis Confirming that Spontaneous Recovery in LHON is rare in the Journal of Neuro-Ophthalmology

15 September 2020

GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

14 Sep 2020 - 16 Sep 2020

H.C. Wainwright 22nd Annual Global Investment Conference – Virtual Conference

04 August 2020

GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital

30 July 2020

GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 13
  • View next 9 articles
© 2022 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page